Suggested remit - To appraise the clinical and cost effectiveness of angiotensin ll within its marketing authorisation for the treatment of hypotension adults with septic or other distributive shock who remain hypotensive following catecholamines and other vasopressor therapies
Topic is suspended
Status Suspended
Process STA 2018
ID number 1588

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
06 February 2020 Suspended. Topic is suspended
06 February 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock. Please note that following on from advice received from the company NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
16 July 2019 (14:00) Scoping workshop (Manchester)
24 May 2019 - 24 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance